Safety Signals Force Enanta To Stop EDP-721 HBV Program

by Vandana Singh, Benzinga Editor

November 19, 2021 7:15 AM | 1 min read | Make a Comment

Enanta Pharmaceuticals Inc ENTA has decided to discontinue the development of EDP-721, an oral Hepatitis B Virus (HBV) RNA destabilizer.
The move follows safety signals observed in the single ascending dose part of a Phase 1 study in healthy volunteers.
"Despite the clean preclinical safety profile demonstrated in comprehensive toxicology studies, safety signals were seen in healthy subjects after administration of EDP-721.
The Company will continue to focus on developing EDP-514 in combination regimens as a functional cure for HBV.
Related: Enanta To Discontinue Internal Development Of NASH Candidates.
Price Action: ENTA shares closed at $92.58 on Thursday.

Posted In: Biotech News Health Care Small Cap General Briefs Hepatits B Phase 1 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.